2024 annual financial data
Halozyme Therapeutics 2024 Operating cash flow growth
Direct answer
Operating cash flow growth was 23.29%.
Operating income was 551,475,000 USD and net income was 444,091,000 USD.
Operating cash flow was 479,064,000 USD.
Get free Halozyme Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 1,015,324,000 USD
- Operating income
- 551,475,000 USD
- Net income
- 444,091,000 USD
- Operating cash flow
- 479,064,000 USD